SCHEMBL6822079

SCHEMBL6822079

CC(C)n1nc(-c2c(-c3ccccc3)nn3ccc(N4CCN(S(=O)(=O)c5ccccc5)CC4)cc23)ccc1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
HTR6 P50406 2/20 0.38
HTR1A P08908 1/20 0.38
DRD2 P14416 1/20 0.38
HSD17B10 Q99714 3/20 0.37
USP2 O75604 2/20 0.37
MAPK1 P28482 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HIF1A Q16665 1/20 0.37
LMNA P02545 2/20 0.36
PKM P14618 1/20 0.36
HTT P42858 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ADORA1 P30542 1/20 0.36
PTGDR Q13258 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6822080 0.91 ADORA1 (0.37) HSD17B10USP2MAPK1ALDH1A1HPGD
SCHEMBL6822552 0.89 ADORA1 (0.40) SMN1; SMN2MEN1KMT2AADORA1
SCHEMBL6822496 0.88 ADORA1 (0.42) HTR6HTR1ADRD2HTTADORA1
SCHEMBL6822588 0.85 ADORA1 (0.41) GAAHTR6HSD17B10USP2MAPK1
SCHEMBL6822109 0.85 ADORA1 (0.41) ALDH1A1SMN1; SMN2LMNAADORA1
SCHEMBL6822056 0.85 KHK (0.43) HTR6HTR1ADRD2LMNAMEN1
SCHEMBL6822057 0.84 ADORA1 (0.41) HTR6HSD17B10USP2MAPK1SMN1; SMN2
SCHEMBL6821993 0.84 KHK (0.41) NPSR1HSD17B10MAPK1ALDH1A1HPGD
SCHEMBL6818374 0.84 BRD4 (0.39) DRD2HSD17B10USP2ALDH1A1LMNA
SCHEMBL6822097 0.83 ADORA1 (0.39) GAANPSR1MAPK1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof ADRB1, ADRA1D, ADRB3 GAA 2865/4885NPSR1 39/4885TDP1 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.